NCT01731626: Pemetrexed Disodium and Cisplatin in Treating Patients Undergoing Surgery For Stage I-III Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 52 | US | cisplatin, CACP, CDDP, CPDD, DDP, pemetrexed disodium, ALIMTA, LY231514, MTA, laboratory biomarker analysis, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, fludeoxyglucose F 18, 18FDG, FDG, therapeutic conventional surgery | Roswell Park Cancer Institute, National Cancer Institute (NCI), Eli Lilly and Company | Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | 04/11 | | | |